Skip to main content

Ipsen

Ipsen S.A. is a French biopharmaceutical company focused on the innovation and commercialization of specialty medicines worldwide. The company concentrates its pipeline and commercial operations across three core therapeutic areas: Oncology, Rare Diseases, and Neuroscience. Key flagship products encompass Somatuline for neuroendocrine tumors, Dysport for spasticity and aesthetic treatments, and Cabometyx for renal cell carcinoma. Primary revenue drivers are global prescription sales of specialty pharmaceuticals to health systems, specialty pharmacies, and wholesalers. Ipsen holds a major international market position in targeted specialty biopharmaceuticals. The company is headquartered in Boulogne-Billancourt, France, and its shares are listed on Euronext Paris.

42 of the funds FundTelligence covers report a position in Ipsen.

Legal name
Ipsen S.A.
Sector
Health Care
Country
France
Funds holding it
42

Funds holding Ipsen

Showing the 8 largest of 42 funds holding it.

Loading...